For SCLC patients, we observed both an upregulation (i.e. CRP, TFRC, ANPEP, SAA1, SAA2, ORM1, and HP) and downregulation (i.e. FCN2) of inflammation markers. This evidence concerns the gene FCN2 and small cell lung carcinoma.